- The company has filed patent applications for two routes of chemical synthesis of ibogaine – offering potential advantages of improved isomeric purity, chiral purity, and easily isolated intermediate compounds
- Preliminary data indicates that the drug shows promise as a treatment for neuropathic pain and migraines, as well as the treatment of addiction
- The company is positioned to engage several markets, including digital therapeutics and research
Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”), a diversified life sciences company at the forefront of the mental health industry, recently announced the launch of its second manufacturing stage of pharmaceutical-grade ibogaine to be used in psychedelic clinical research. During this stage of manufacturing, the company will be assessing the quality of the synthetic ibogaine to be produced at scale to determine the timing and cost for commercial-scale manufacturing (
https://ibn.fm/xOXo9).
Kelsey Ramsden, President and CEO of MINDCURE, spoke on the manufacturing goals stating, “We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at
http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit
https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the
InvestorBrandNetwork.